Literature DB >> 3182344

Nasopharyngeal carcinoma in Saudi Arabia: a retrospective study of 166 cases treated with curative intent.

G E Laramore1, B Clubb, C Quick, M H Amer, M Ali, W Greer, E Mahboubi, M el-Senoussi, H Schultz, S M el-Akkad.   

Abstract

A retrospective review was performed of the medical records of 166 adult patients with biopsy-proven carcinomas of the nasopharynx treated with curative intent at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. All patients were treated between June 1975 and December 1985 using megavoltage therapy equipment. Most patients presented with advanced nodal disease: 23 patients (13.9%) were N0, 16 patients (9.6%) were N1, 29 patients (17.5%) were N2, and 98 patients (59%) were N3. The overwhelming majority of patients had nonkeratinizing lesions (158/166). At the time of analysis, mean follow-up time was 24.2 months (range 2-108). Actuarial curves are presented for local/regional control as a function of T-stage and N-stage and for survival and time to development of distant metastases as a function of N-stage. At 4 years local/regional control was 70% for T1 lesions, 59% for T2 lesions, 30% for T3 lesions, and 35% for T4 lesions. There was little correlation between local/regional control and N-stage being about 50% at 4 years for all nodal subgroups. Only six patients exhibited an isolated first failure in the regional nodes alone, whereas 60 patients failed initially at the primary site (either alone or in conjunction with a simultaneous nodal failure). The development of distant metastases correlated to some extent with nodal disease ranging from 20% at 4 years for T1/T2 N0 patients to 70% for patients who initially presented with N3 disease. Survival data was more difficult to obtain due to cultural biases in a medically unsophisticated patient population. True survival curves are bounded by calculating actuarial curves in two ways: death as the failure endpoint and death plus lost-with-active-disease as failure endpoints. In terms of the latter curves, at 4 years "survival" ranged from 39% for patients with T1/T2 N0 lesions to 23% for patients with N3 lesions.

Entities:  

Mesh:

Year:  1988        PMID: 3182344     DOI: 10.1016/0360-3016(88)90193-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian centres from 1977 to 2000. Part I: Evolving technical choices and survival.

Authors:  S Tonoli; S M Magrini; L Costa; F Paiar; G Simontacchi; V Scotti; N Pasinetti; R Barca; D Barbieri; A De Stefani; E Cellai; M Buglione; G Biti
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

2.  Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population.

Authors:  M Tang; Y Zeng; A Poisson; D Marti; L Guan; Y Zheng; H Deng; J Liao; X Guo; S Sun; G Nelson; G de Thé; C A Winkler; S J O'Brien; M Carrington; X Gao
Journal:  Genes Immun       Date:  2010-01-14       Impact factor: 2.676

3.  Genetic factors leading to chronic Epstein-Barr virus infection and nasopharyngeal carcinoma in South East China: study design, methods and feasibility.

Authors:  Xiu Chan Guo; Kevin Scott; Yan Liu; Michael Dean; Victor David; George W Nelson; Randall C Johnson; Holli H Dilks; James Lautenberger; Bailey Kessing; Janice Martenson; Li Guan; Shan Sun; Hong Deng; Yuming Zheng; Guy de The; Jian Liao; Yi Zeng; Stephen J O'Brien; Cheryl A Winkler
Journal:  Hum Genomics       Date:  2006-06       Impact factor: 4.639

4.  Outcomes of Saudi Arabian Patients With Nasopharyngeal Cancer Treated With Primarily Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy.

Authors:  Rolina Al-Wassia; Atlal Abusanad; Nesreen Awad; Hani Marzouki; Shadi Alkhayyat; Talal Al-Khatib; Camelia Constantinescu
Journal:  J Glob Oncol       Date:  2016-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.